Poliovirus Receptor Antikörper (PE)

Produktnummer ABIN2663054

Der PE-konjugierte Maus Monoklonal anti-Poliovirus Receptor Antikörper (Klon SKII-4) (ABIN2663054) detektiert spezifisch Poliovirus Receptor in FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Poliovirus Receptor Antikörper (PE) (ABIN2663054)

Target: Poliovirus Receptor (PVR)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Poliovirus Receptor Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: SKII-4

Produktdetails anti-Poliovirus Receptor Antikörper (PE)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu Poliovirus Receptor

Target: Poliovirus Receptor (PVR)

Andere Bezeichnung: CD155

Hintergrund: CD155, known as poliovirus receptor (PVR) or nectin-like 5, is a 70 kD type I transmembrane glycoprotein. It is a nectin-like molecule belonging to Ig superfamily. CD155 is primarily found on endothelial cells, monocytes, epithelia and central nervous system. CD155 is an adhesion molecule involved in cell-cell and cell-matrix adhesion through interaction with CD226, CD96 (Tactile), nectin-1, -2, and -3 (CD111, CD112, CD113), and vitronectin. It also serves as a receptor for poliovirus and cytomegalovirus.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interaktom